Targeting the Genetic Drivers of Cancer

Kinnate Biopharma is driven by the urgency of cancer patients who need more effective therapies. By using next-generation genomic, molecular, and medicinal chemistry tools, we have built a best-in-class and first-in-class portfolio of kinase inhibitors targeting hard-to-treat, genetically defined cancers. To help move our programs forward, Kinnate has brought together an experienced and nimble team of drug discovery experts, precision oncology leaders and world-class life science investors.

“Kinnate has assembled an experienced team of drug hunters who have built, from the ground up, a pipeline of best-in-class and first-in-class precision medicines that have the potential to deliver better outcomes for patients fighting hard-to-treat cancers.”

– Keith T. Flaherty, MD, Kinnate Board and SAB Member

Unmet Need in Cancer Therapeutics

With significant innovation in genomic sequencing technology, oncogenic mutations and fusions are routinely profiled in cancer patients which has enabled the rapid advance of precision medicine. However, it is estimated that only 8% of cancers are addressable with existing precision therapies that target these alterations or inhibit them sufficiently to provide sustained clinical benefit.

Our focus is on the design and development of selective small molecules targeting mutations and fusions with no coverage currently. By first identifying a specific patient population that expresses a certain molecular mutation driving oncogenesis, we focus on developing the right drug targeted to the right genetically defined cancer.

Through our commitment to precision oncology, we have identified best-in-class and first-in-class candidates targeting RAF, FGFR2/3 and CDK12 as well as other novel targets.


“There are clear drivers of disease and resistance mutations that will cause current therapies to fail. The Kinnate portfolio addresses these challenges and will potentially contribute meaningful new medicines to patient populations that would benefit from them.”

– Ryan Corcoran, MD, PhD, Kinnate SAB Member

An Experienced Team of Precision Oncology Leaders

A Focused Pipeline Portfolio